ChemotherapyFDA-approvedSecond-line
Taxotere
Generic name: docetaxel
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median overall survival of approximately 18 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Setidegrasib and Docetaxel for Non-small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Ivonescimab with Chemotherapy in Early-Stage Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Docetaxel for Prostate Cancer After Radiation Therapy | Prostate Cancer | phase-2 | — | Source → |
| Comparing Two Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median prostate cancer-specific survival from the initiation of DTX was 16.1 months in the ENZ-DTX group and 25.3 months in the ABI-DTX group. | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Insights into Cancer Treatment with Sacituzumab Govitecan | Lung Cancer | phase-3 | Median overall survival with sacituzumab govitecan versus docetaxel was 8.9 versus 9.8 months (hazard ratio [HR] = 0.96, 95% CI: 0.68-1.38) and 11.8 versus 10.7 months (HR = 0.89, 95% CI: 0.60-1.32) in subgroups with Trop-2 histological scores greater than or equal to the median and less than the median, respectively. | Source → |
| Researchers Investigate Combination Therapy for Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Testing Ceralasertib and Durvalumab in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Eribulin vs. Taxanes for HER2-Positive Breast Cancer | Breast Cancer | phase-3 | Progression-free survival was 14.0 months with eribulin vs. 13.1 months with docetaxel, and 14.1 months with eribulin vs. 10.8 months with paclitaxel. | Source → |
| New Treatment Options for Lung Cancer Patients | Lung Cancer | observational | The disease control rate was significantly higher in patients receiving PD-1 blockade-based regimens at 82.8% compared with 54.0% in the control group. | Source → |
| Testing a New Treatment for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Docetaxel Side Effect in Breast Cancer Patients | Breast Cancer | review | — | Source → |
| Evaluating Treatment Intensification for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Tislelizumab Improves Outcomes in Advanced Lung Cancer | Lung Cancer | phase-3 | The median overall survival was 16.9 months versus 11.9 months for tislelizumab versus docetaxel in the ITT population. | Source → |
| Sotorasib Outperforms Docetaxel in Lung Cancer Treatment | Lung Cancer | observational | Sotorasib was associated with a 36.7% decreased risk of death and a 43.3% decreased risk of treatment discontinuation or death compared to docetaxel. | Source → |
| Breast Cancer Cells Less Sensitive to Chemotherapy Due to Specific RNA | Breast Cancer | lab-study | — | Source → |
| Testing Radium-223 with Docetaxel in Prostate Cancer Patients | Prostate Cancer | phase-3 | — | Source → |
| New Study Examines Effectiveness of Docetaxel Plus Ramucirumab After Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 33.3% (90% CI, 19.9-49.1), and the disease control rate was 90.9% (90% CI, 78.1-97.5). | Source → |
| Real-World Outcomes of Docetaxel in Lung Cancer Patients | Lung Cancer | observational | Median overall survival was 6.5 months (95% CI, 5.9-7.3). | Source → |
| Evaluating a New Treatment Combination for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Study Examines Effectiveness of Docetaxel and Ramucirumab for Lung Cancer Symptoms | Lung Cancer | observational | The pleural effusion control rate was 87%, and the cerebral edema control rate was 26%. | Source → |
| Testing BNT324 for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| ONC-392 vs Docetaxel for Lung Cancer That Has Progressed | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatments for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a Combination of Medications for HER2-Positive Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study of Darolutamide in Combination with Androgen Deprivation Therapy and Docetaxel for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing a New Treatment to Docetaxel for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Comparing BL-B01D1 to Docetaxel in Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Evaluating a Lower-Dose Chemotherapy Combination for Older Women with Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Green Tea and Quercetin Combined with Chemotherapy in Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Testing ADI-PEG 20 with Gemcitabine and Docetaxel for Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Ivonescimab with Docetaxel for Advanced Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Docetaxel with Hormonal Therapy and Apalutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing Treatments for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Treatment Combination Shows Promise for Prostate Cancer Patients | Prostate Cancer | phase-2 | At week 12, 67.7% of patients showed a response in prostate-specific antigen (PSA) levels. | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for HER2 Positive Breast Cancer | Breast Cancer | phase-3 | Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004). | Source → |
| Evaluating Nivolumab and Docetaxel for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Study of a New Medicine for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Insights into Prostate Cancer Treatment Options | Prostate Cancer | meta-analysis | Darolutamide + docetaxel + ADT showed significant benefit over docetaxel + ADT, ADT and standard-nonsteroidal-antiandrogen + ADT in all analyses. | Source → |
| New Insight into Docetaxel Resistance in Prostate Cancer | Prostate Cancer | lab-study | Treatment with an OTUB2 inhibitor resensitized resistant CRPC to docetaxel. | Source → |
| PIGL's role in prostate cancer resistance to docetaxel treatment | Prostate Cancer | lab-study | — | Source → |
| Liposomes Help Deliver Cancer Medicine to Prostate Cancer Cells | Prostate Cancer | review | — | Source → |
| Combination Therapy for Lung Cancer May Have Different Side Effects | Lung Cancer | observational | — | Source → |
| Severe Neutropenia Risk in Prostate Cancer Patients on Cabazitaxel | Prostate Cancer | observational | — | Source → |
| Eugenol Derivatives Enhance Chemotherapy Effectiveness in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| Chemotherapy Combination Affects Lung Cancer Cells in Lab Experiments | Lung Cancer | lab-study | — | Source → |
| Hospitalization Risks Vary for Prostate Cancer Patients on Different Treatments | Prostate Cancer | observational | — | Source → |
| Early Docetaxel and Enzalutamide for Prostate Cancer: New Insights | Prostate Cancer | phase-3 | Among those assigned no enzalutamide, OS was longer with the planned use of early docetaxel (HR 0.90, 95% CI 0.82-0.98), especially in high-volume disease. | Source → |
| METTL14's Role in Lung Cancer Progression and Docetaxel Resistance | Lung Cancer | lab-study | — | Source → |
| Atezolizumab Compared to Docetaxel in Lung Cancer Treatment | Lung Cancer | meta-analysis | Atezolizumab had better efficacy than docetaxel for overall survival (HR: 0.77, 95% CI: 0.73 to 0.81). | Source → |
| New Nanoparticle Delivery System Shows Promise for Breast Cancer Treatment | Breast Cancer | lab-study | The cRGD-HA-CDU@DTX system exhibited a 64.12% tumor growth reduction. | Source → |
| New Delivery System for Cancer Drug Shows Promise | Prostate Cancer | lab-study | Docetaxel-bound nanoparticles significantly reduced the viability of the tumor cell compared to the healthy cell in a dose-dependent manner, especially at 24 (50.14 ± 13.25 to 22.32 ± 5.51 at 100 µg/mL) h and 48 (41.46 ± 2.22 to 18.80 ± 2.81 at 100 µg/mL) h. | Source → |
| New Nanofibrous Mats Deliver Cancer-Fighting Medicine Directly to Prostate Cancer Sites | Prostate Cancer | lab-study | — | Source → |
| Prostate Cancer Cells May Resist Chemotherapy Due to Protein Interactions | Prostate Cancer | lab-study | — | Source → |
| AGD1 Complex May Reduce Effectiveness of Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Traditional Chinese Medicine May Help Overcome Prostate Cancer Resistance to Treatment | Prostate Cancer | lab-study | — | Source → |
| Real-world safety of docetaxel for lung cancer treatment | Lung Cancer | observational | — | Source → |
| DRG2 levels predict response to PARP inhibitors in prostate cancer cells | Prostate Cancer | lab-study | — | Source → |
| Cancer Cells Develop Resistance to Chemotherapy | Breast Cancer | lab-study | — | Source → |
| GRIM-19's Role in Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| New way to deliver cancer drug may reduce side effects | Breast Cancer | lab-study | The encapsulated drug indicated higher cytotoxicity on MCF-7 cells and the half inhibitory concentration (IC) value was 2 µg/ml after 72 h. | Source → |
| Prostate Cancer Cells May Resist Treatment Due to Exosome-Released Molecule | Prostate Cancer | lab-study | — | Source → |
| Liquid Biopsy Predicts Treatment Response in Prostate Cancer Patients | Prostate Cancer | phase-3 | LBRB-positive patients had no benefit from continuing enzalutamide with docetaxel (HR = 0.78, 95% CI = 0.41-1.48, p = 0.44; RMST: 7.9 vs 7.1 mo, p = 0.50). | Source → |
| Researchers Identify Pathway Behind Docetaxel Resistance in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| Targeted Nanoparticles Show Promise in Treating Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Combining drugs to overcome cancer resistance | Lung Cancer | lab-study | — | Source → |
| Cost-Effectiveness of Sotorasib for Lung Cancer Patients in China | Lung Cancer | phase-3 | — | Source → |
| Dexamethasone May Help Reduce Hand-Foot Syndrome in Breast Cancer Patients | Breast Cancer | observational | Development of all-grade hand-foot syndrome in all treatment cycles was significantly lower in the 8 mg group (50.0%) than in the 4 mg group (73.0%). | Source → |
| Previous Cancer Treatment May Affect Neutropenia Risk in Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Targeting Glutamine Metabolism in Resistant Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Prostate Cancer Protein Degradation May Help Combat Resistance to Docetaxel | Prostate Cancer | lab-study | — | Source → |
| Docetaxel treatment creates large, polyploid cancer cells in ovarian cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Turmeric Compound with Standard Prostate Cancer Treatment May Improve Effectiveness | Prostate Cancer | lab-study | — | Source → |
| NOTCH3 linked to docetaxel resistance in prostate cancer | Prostate Cancer | lab-study | — | Source → |
| Combining two drugs slows prostate cancer growth in lab experiments | Prostate Cancer | lab-study | The combination of CUDC-101 and DTX significantly reduced tumor growth, as evidenced by lower tumor weight and volumes. | Source → |
| Symptoms of Breast Cancer Patients Before and After Chemotherapy | Breast Cancer | observational | — | Source → |
| New Lung Cancer Treatment Combination Shows Mixed Results | Lung Cancer | phase-3 | The clinical benefit rate was 75.5% for sitra + nivo and 64.5% for docetaxel. | Source → |
| Combining Cancer Treatments for Prostate Cancer: What's the Best Combination? | Prostate Cancer | review | — | Source → |
| Abiraterone Acetate May Be Better Than Docetaxel for Prostate Cancer | Prostate Cancer | observational | The abiraterone acetate group demonstrated significantly better progression-free survival (PFS) than the docetaxel group (not reached vs. 15.1 months: hazard ratio = 0.37; 95% confidence interval = 0.28-0.50; P < .001). | Source → |
| New Cancer Treatment Combination Tested in Ovarian Cancer Patients | Ovarian Cancer | phase-1 | — | Source → |
| Polysaccharides from Lentinus edodes may help prostate cancer treatment | Prostate Cancer | lab-study | — | Source → |
| Dexamethasone May Reduce Oral Mucositis in Breast Cancer Patients | Breast Cancer | observational | The incidence of all-grade oral mucositis in the first cycle was 57.8% in the low-dose group and 19.2% in the high-dose group. | Source → |
| New Carrier Material Helps Deliver Cancer Drugs More Effectively | Ovarian Cancer | lab-study | TPGS-CHMC/DTX micelles displayed significantly higher anti-tumour activity and less toxicity than the free DTX solution. | Source → |
| Link Found Between Resistance to Two Prostate Cancer Drugs | Prostate Cancer | lab-study | — | Source → |
| Understanding Resistance to Prostate Cancer Treatments | Prostate Cancer | review | — | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median time to castration-resistant prostate cancer in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). | Source → |
| Ramucirumab plus docetaxel for lung cancer after immunotherapy | Lung Cancer | review | The pooled weighted median progression-free survival was 5.7 months, and the median overall survival was 11.2 months in the RAM + DTX ICI pre-treated group. | Source → |
| Generic vs. Brand Docetaxel in Breast Cancer Treatment | Breast Cancer | observational | — | Source → |
| Docetaxel Inhibits Prostate Cancer Cell Growth | Prostate Cancer | lab-study | — | Source → |
| Triplet Therapy Shows Promise for Prostate Cancer Treatment | Prostate Cancer | meta-analysis | Triplet therapy with darolutamide or abiraterone with docetaxel and ADT improved overall survival, with a hazard ratio of 0.70 (95%CI 0.61-0.80) compared to docetaxel+ADT. | Source → |
| Reusing a Cancer Treatment May Help Some Prostate Cancer Patients | Prostate Cancer | observational | Among 54 evaluable patients, 27.8% had a PSA decline ≥50%. | Source → |
| Continuing Enzalutamide May Delay Cancer Progression in Some Patients | Prostate Cancer | phase-3 | — | Source → |
| Exosomal RNA May Contribute to Prostate Cancer Resistance to Docetaxel | Prostate Cancer | lab-study | — | Source → |
| Fucoidan May Help Treat Docetaxel-Resistant Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Docetaxel Response Affects Cabazitaxel Sensitivity in Prostate Cancer | Prostate Cancer | observational | None of the patients with a poor response to prior docetaxel therapy responded well to cabazitaxel therapy. | Source → |
| Docetaxel for Early Prostate Cancer: New Long-Term Results | Prostate Cancer | phase-3 | The 5-year metastasis-free survival rate was 82% with SOC plus docetaxel vs 77% with SOC. | Source → |
| Abiraterone and Docetaxel Compared in Prostate Cancer Treatment | Prostate Cancer | observational | The ABI group had a significantly better castration-resistant prostate cancer (CRPC)-free survival than the DOC group [hazard ratio (HR), 0.53; 95% confidence interval (CI), 0.34-0.82]. | Source → |
| New Lung Cancer Treatment Combination Shows Promise in China | Lung Cancer | phase-2 | The median progression-free survival was 5.8 months, and the progression-free survival rates at 6 and 12 months were 48% and 30%, respectively. | Source → |
| Docetaxel Works Similarly in Two Types of Prostate Cancer Patients | Prostate Cancer | lab-study | — | Source → |
| New Cancer Gene Linked to Resistance to Common Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Adding Docetaxel or Abiraterone to Prostate Cancer Treatment May Improve Survival | Prostate Cancer | phase-3 | Patients receiving upfront ABI had significantly better CRPCFS than those receiving ADT/CAB or upfront DOC [hazard ratio (HR) 0.39; 95% CI 0.27-0.56]. | Source → |
| Nintedanib and Docetaxel May Help Some Lung Cancer Patients | Lung Cancer | observational | Each patient achieved a partial response with nintedanib plus docetaxel, with response duration from 8 months to over 30 months. | Source → |
| BMI's Effect on Docetaxel Outcomes in Prostate Cancer Patients | Prostate Cancer | phase-3 | Overweight and obese patients had significantly better overall survival compared with lean patients, with hazard ratios of 0.68 and 0.59, respectively. | Source → |
| Chemotherapy's Short-Term Impact on Prostate Cancer Patients | Prostate Cancer | phase-3 | FACT-P scores decreased in Arm A at the end of treatment and remained unchanged in Arm B (p<0.0001). | Source → |
| Docetaxel and Hormone Therapy Tested in Prostate Cancer Patients | Prostate Cancer | phase-2 | The median CRPC-free survival was 26.4 months with a one-year CRPC-free rate of 79%. | Source → |
| Researchers Explore How Cancer Cells Resist Treatment | Lung Cancer | lab-study | — | Source → |
| New Chemotherapy Combination Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | phase-2 | 61.4% of patients in the DCb group achieved a pathologic complete response. | Source → |
| Prostate Cancer Study Links Blood Test Ratio to Treatment Outcomes | Prostate Cancer | observational | The median progression-free survival was 9.8 vs 7.5 months, and overall survival was 17.6 vs 14.2 months in patients with a lower vs higher neutrophil-to-lymphocyte ratio. | Source → |
| Different Response to Cancer Treatment in Two Types of Tumors | Lung Cancer | observational | — | Source → |
| Docetaxel Affects Ovarian Cancer Cells' Structure and Strength | Ovarian Cancer | lab-study | When the concentration of docetaxel was 100 ng/ml, the adhesion decreased by 37.04% and Young's modulus increased by 1.57 times compared with the control group. | Source → |
| G-CSF May Help Reduce Severe Side Effects in Breast Cancer Patients | Breast Cancer | observational | The rate of febrile neutropenia was 6.2% in the G-CSF group compared to 15.7% in the non-G-CSF group. | Source → |
| DRG2 levels affect how prostate cancer cells respond to docetaxel | Prostate Cancer | lab-study | In PC3 and DU145 cell lines, DRG2 knockdown increased docetaxel-induced Annexin V (+) apoptosis by 8.7 and 2.7 times, respectively. | Source → |
| Modeling Tumor Growth in HER2-Negative Breast Cancer Patients | Breast Cancer | phase-2 | — | Source → |
| Tau protein buildup makes prostate cancer cells more sensitive to treatment | Prostate Cancer | lab-study | — | Source → |
| Gold Nanoparticles Deliver Cancer Drug to Prostate Cancer Cells | Prostate Cancer | lab-study | The drug encapsulated nanoformulations reduced the cell viability to about 40% at 40 µM concentration after 24, 48, and 72 hours of treatment. | Source → |
| Predicting Docetaxel Side Effects in Prostate Cancer Patients | Prostate Cancer | phase-3 | — | Source → |
| Atezolizumab May Help Lung Cancer Patients with Certain Genetic Mutations | Lung Cancer | phase-3 | Median overall survival was 7.3 months in the atezolizumab group versus 5.8 months in the docetaxel group. | Source → |
| 4-Weekly Docetaxel Treatment for Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Researchers Explore New Way to Make Prostate Cancer Treatment More Effective | Prostate Cancer | lab-study | — | Source → |
| Docetaxel Rechallenge May Improve Survival in Prostate Cancer Patients | Prostate Cancer | observational | The median overall survival was 50.11 months in the rechallenge group, as compared to 26.36 months in the non-rechallenge group. | Source → |
| Chemotherapy after Prostate Cancer Treatment: New Insights | Prostate Cancer | meta-analysis | The meta-analysis showed a slightly OS improvement (HR: 0.79; 95% CI, 0.63-0.98; p = 0.03) with docetaxel. | Source → |
| Targeted Cancer Treatment Using Nanoparticles | Prostate Cancer | lab-study | The nanoparticles showed 2.79-fold lower IC values than free docetaxel. | Source → |
| Testosterone Levels May Influence Effectiveness of Prostate Cancer Treatment | Prostate Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.